Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 311,288,032
  • Shares Outstanding, K 6,363,206
  • Annual Sales, $ 70,874 M
  • Annual Income, $ 9,402 M
  • EBIT $ 0 M
  • EBITDA $ 19,129 M
  • 60-Month Beta 0.46
  • Price/Sales 4.51
  • Price/Cash Flow 14.74
  • Price/Book 7.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/06/25
  • Annual Dividend & Yield 0.87 (1.78%)
  • Most Recent Dividend 0.873 on 03/28/25
  • Sector Medical
  • INDUSTRY GROUPING Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.5200 +18.95%
on 11/05/25
49.2000 -2.03%
on 11/18/25
+7.7000 (+19.01%)
since 11/04/25
3-Month
39.5000 +22.03%
on 09/26/25
49.2000 -2.03%
on 11/18/25
+5.4600 (+12.77%)
since 09/04/25
52-Week
34.1030 +41.34%
on 12/19/24
49.2000 -2.03%
on 11/18/25
+12.3100 (+34.30%)
since 12/04/24

Most Recent Stories

More News
Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here?

Olema stock soared Tuesday after Roche reported strong clinical results for its breast cancer drug. An Oppenheimer analyst sees significant further upside in OLMA shares to $45.

OLMA : 27.64 (+1.43%)
RHHBY : 48.2000 (-1.47%)
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer

-At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapy- -These unprecedented...

RHHBY : 48.2000 (-1.47%)
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche

BASEL, Switzerland , Nov. 12, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today research findings showing that 31% of eligible millennials have postponed or missed their cervical...

ROG : 87.20 (-0.76%)
RHHBY : 48.2000 (-1.47%)
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - ...

RHHBY : 48.2000 (-1.47%)
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025

– Findings further demonstrate the effectiveness of Genentech’s approved medicines in advancing treatment standards for people with blood disorders – – Data from...

RHHBY : 48.2000 (-1.47%)
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

– Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion – – Gazyva...

RHHBY : 48.2000 (-1.47%)
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome

– Gazyva versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 – – If approved, Gazyva...

RHHBY : 48.2000 (-1.47%)
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment

– Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo – – IMvigor011 is the first global Phase III...

RHHBY : 48.2000 (-1.47%)
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20...

RHHBY : 48.2000 (-1.47%)
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer

– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care...

RHHBY : 48.2000 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 49.6833
2nd Resistance Point 49.3567
1st Resistance Point 48.7783
Last Price 48.2000
1st Support Level 47.8733
2nd Support Level 47.5467
3rd Support Level 46.9683

See More

52-Week High 49.2000
Last Price 48.2000
Fibonacci 61.8% 43.4329
Fibonacci 50% 41.6515
Fibonacci 38.2% 39.8701
52-Week Low 34.1030

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar